ONTOLOGY REPORT - ANNOTATIONS
| Term: | amiloride |
|
| Accession: | CHEBI:2639
|
browse the term
|
| Definition: | A pyrazine that has formula C6H8ClN7O. |
| Synonyms: | exact_synonym: | 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide |
| | related_synonym: | C6H8ClN7O; InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15); InChIKey=XSDQTOBWRPYKKA-UHFFFAOYSA-N; N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; NC(=N)NC(=O)c1nc(Cl)c(N)nc1N; amilorida; amiloridum |
| | xref_casrn: | 2609-46-3 |
| | xref: | Beilstein:616612 "Beilstein Registry Number"; ChEMBL:189526 "ChEMBL COMPOUND"; ChemIDplus:2609-46-3 "CAS Registry Number"; DrugBank:DB00594 "DrugBank"; KEGG COMPOUND:2609-46-3 "CAS Registry Number"; KEGG COMPOUND:C06821 "KEGG COMPOUND"; KEGG DRUG:D07447 "KEGG DRUG" |
| | xref_mesh: | MESH:D000584 |
| | xref: | Patent:BE639386 "Patent"; Patent:US3313813 "Patent"; Wikipedia:Amiloride "Wikipedia" |
|
|
amiloride
|
| G |
Abp1 |
amiloride binding protein 1 (amine oxidase, copper-containing) |
|
affects binding |
ISO |
4 |
76,957,477 |
76,977,643 |
RGD:6480464 |
CTD |
| G |
Abp1 |
amiloride binding protein 1 (amine oxidase, copper-containing) |
|
decreases activity |
ISO |
4 |
76,957,477 |
76,977,643 |
RGD:6480464 |
CTD |
| G |
Abp1 |
amiloride binding protein 1 (amine oxidase, copper-containing) |
|
multiple interactions |
ISO |
4 |
76,957,477 |
76,977,643 |
RGD:6480464 |
CTD |
| G |
Acan |
aggrecan |
|
affects expression |
EXP |
1 |
134,787,341 |
134,848,992 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
increases expression |
ISO |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
multiple interactions |
EXP |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Asic3 |
acid-sensing (proton-gated) ion channel 3 |
|
affects response to substance |
ISO |
4 |
6,125,614 |
6,129,660 |
RGD:6480464 |
CTD |
| G |
Atp1a1 |
ATPase, Na+/K+ transporting, alpha 1 polypeptide |
|
multiple interactions |
EXP |
2 |
196,657,749 |
196,687,242 |
RGD:6480464 |
CTD |
| G |
Atp6v1b1 |
ATPase, H transporting, lysosomal V1 subunit B1 |
|
multiple interactions |
EXP |
4 |
117,931,972 |
117,950,626 |
RGD:6480464 |
CTD |
| G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
|
multiple interactions |
ISO |
10 |
14,621,372 |
14,679,051 |
RGD:6480464 |
CTD |
| G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
|
multiple interactions |
ISO |
10 |
14,621,372 |
14,679,051 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
ISO |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
decreases expression |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
multiple interactions |
ISO |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
|
increases activity |
ISO |
4 |
43,874,852 |
44,041,870 |
RGD:6480464 |
CTD |
| G |
Col2a1 |
collagen, type II, alpha 1 |
|
affects expression |
EXP |
7 |
136,679,219 |
136,707,976 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
multiple interactions |
ISO |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Ddit3 |
DNA-damage inducible transcript 3 |
|
multiple interactions |
ISO |
7 |
67,247,749 |
67,252,571 |
RGD:6480464 |
CTD |
| G |
Dysf |
dysferlin |
|
decreases expression |
ISO |
4 |
118,213,435 |
118,371,283 |
RGD:6480464 |
CTD |
| G |
Eif2a |
eukaryotic translation initiation factor 2A |
|
increases phosphorylation |
ISO |
2 |
147,870,265 |
147,903,411 |
RGD:6480464 |
CTD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
decreases phosphorylation |
ISO |
10 |
87,219,157 |
87,242,919 |
RGD:6480464 |
CTD |
| G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
|
multiple interactions |
ISO |
10 |
95,794,488 |
95,855,895 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Hspa5 |
heat shock protein 5 |
|
multiple interactions |
ISO |
3 |
13,783,825 |
13,788,022 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
ISO |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Itgal |
integrin, alpha L |
|
multiple interactions |
ISO |
1 |
186,561,795 |
186,598,908 |
RGD:6480464 |
CTD |
| G |
Klk1 |
kallikrein 1 |
|
increases response to substance |
ISO |
1 |
94,624,828 |
94,628,822 |
RGD:6480464 |
CTD |
| G |
Klk1 |
kallikrein 1 |
|
multiple interactions |
ISO |
1 |
94,624,828 |
94,628,822 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
multiple interactions |
ISO |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Myf5 |
myogenic factor 5 |
|
increases expression |
ISO |
7 |
46,189,256 |
46,192,487 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
|
decreases phosphorylation |
ISO |
10 |
13,329,708 |
13,394,080 |
RGD:6480464 |
CTD |
| G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
|
decreases uptake |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Pkd2 |
polycystic kidney disease 2 (autosomal dominant) |
|
multiple interactions |
ISO |
14 |
6,349,519 |
6,392,988 |
RGD:6480464 |
CTD |
| G |
Plau |
plasminogen activator, urokinase |
|
decreases activity |
ISO |
15 |
3,680,072 |
3,686,232 |
RGD:6480464 |
CTD |
| G |
Plau |
plasminogen activator, urokinase |
|
multiple interactions |
ISO |
15 |
3,680,072 |
3,686,232 |
RGD:6480464 |
CTD |
| G |
Plau |
plasminogen activator, urokinase |
|
decreases activity |
ISO |
15 |
3,680,072 |
3,686,232 |
RGD:6480464 |
CTD |
| G |
Plau |
plasminogen activator, urokinase |
|
decreases activity |
ISO |
15 |
3,680,072 |
3,686,232 |
RGD:6480464 |
CTD |
| G |
Plau |
plasminogen activator, urokinase |
|
decreases activity |
ISO |
15 |
3,680,072 |
3,686,232 |
RGD:6480464 |
CTD |
| G |
Plaur |
plasminogen activator, urokinase receptor |
|
multiple interactions |
ISO |
1 |
79,708,646 |
79,712,881 |
RGD:6480464 |
CTD |
| G |
Plg |
plasminogen |
|
multiple interactions |
ISO |
1 |
42,782,464 |
42,825,149 |
RGD:6480464 |
CTD |
| G |
Ppp1ca |
protein phosphatase 1, catalytic subunit, alpha isozyme |
|
decreases phosphorylation |
ISO |
1 |
206,774,719 |
206,778,336 |
RGD:6480464 |
CTD |
| G |
Ppp1ca |
protein phosphatase 1, catalytic subunit, alpha isozyme |
|
multiple interactions |
ISO |
1 |
206,774,719 |
206,778,336 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Scnn1a |
sodium channel, nonvoltage-gated 1 alpha |
|
multiple interactions |
ISO |
4 |
161,445,936 |
161,469,267 |
RGD:6480464 |
CTD |
| G |
Scnn1a |
sodium channel, nonvoltage-gated 1 alpha |
|
multiple interactions |
ISO |
4 |
161,445,936 |
161,469,267 |
RGD:6480464 |
CTD |
| G |
Scnn1a |
sodium channel, nonvoltage-gated 1 alpha |
|
multiple interactions |
ISO |
4 |
161,445,936 |
161,469,267 |
RGD:6480464 |
CTD |
| G |
Scnn1a |
sodium channel, nonvoltage-gated 1 alpha |
|
affects activity |
ISO |
4 |
161,445,936 |
161,469,267 |
RGD:6480464 |
CTD |
| G |
Scnn1a |
sodium channel, nonvoltage-gated 1 alpha |
|
multiple interactions |
EXP |
4 |
161,445,936 |
161,469,267 |
RGD:6480464 |
CTD |
| G |
Scnn1a |
sodium channel, nonvoltage-gated 1 alpha |
|
multiple interactions |
ISO |
4 |
161,445,936 |
161,469,267 |
RGD:6480464 |
CTD |
| G |
Scnn1b |
sodium channel, nonvoltage-gated 1, beta |
|
multiple interactions |
ISO |
1 |
180,682,622 |
180,748,068 |
RGD:6480464 |
CTD |
| G |
Scnn1b |
sodium channel, nonvoltage-gated 1, beta |
|
multiple interactions |
ISO |
1 |
180,682,622 |
180,748,068 |
RGD:6480464 |
CTD |
| G |
Scnn1b |
sodium channel, nonvoltage-gated 1, beta |
|
multiple interactions |
ISO |
1 |
180,682,622 |
180,748,068 |
RGD:6480464 |
CTD |
| G |
Scnn1b |
sodium channel, nonvoltage-gated 1, beta |
|
affects activity |
ISO |
1 |
180,682,622 |
180,748,068 |
RGD:6480464 |
CTD |
| G |
Scnn1b |
sodium channel, nonvoltage-gated 1, beta |
|
multiple interactions |
ISO |
1 |
180,682,622 |
180,748,068 |
RGD:6480464 |
CTD |
| G |
Scnn1g |
sodium channel, nonvoltage-gated 1, gamma |
|
affects activity |
ISO |
1 |
180,555,660 |
180,589,534 |
RGD:6480464 |
CTD |
| G |
Scnn1g |
sodium channel, nonvoltage-gated 1, gamma |
|
multiple interactions |
ISO |
1 |
180,555,660 |
180,589,534 |
RGD:6480464 |
CTD |
| G |
Scnn1g |
sodium channel, nonvoltage-gated 1, gamma |
|
multiple interactions |
ISO |
1 |
180,555,660 |
180,589,534 |
RGD:6480464 |
CTD |
| G |
Scnn1g |
sodium channel, nonvoltage-gated 1, gamma |
|
multiple interactions |
ISO |
1 |
180,555,660 |
180,589,534 |
RGD:6480464 |
CTD |
| G |
Scnn1g |
sodium channel, nonvoltage-gated 1, gamma |
|
multiple interactions |
ISO |
1 |
180,555,660 |
180,589,534 |
RGD:6480464 |
CTD |
| G |
Sele |
selectin E |
|
multiple interactions |
ISO |
13 |
79,813,455 |
79,822,845 |
RGD:6480464 |
CTD |
| G |
Slc12a4 |
solute carrier family 12 (potassium/chloride transporters), member 4 |
|
multiple interactions |
ISO |
19 |
35,785,181 |
35,807,024 |
RGD:6480464 |
CTD |
| G |
Slc26a4 |
solute carrier family 26, member 4 |
|
multiple interactions |
EXP |
6 |
49,389,212 |
49,427,000 |
RGD:6480464 |
CTD |
| G |
Slc31a1 |
solute carrier family 31 (copper transporters), member 1 |
|
multiple interactions |
ISO |
5 |
79,359,420 |
79,385,988 |
RGD:6480464 |
CTD |
| G |
Slc47a1 |
solute carrier family 47, member 1 |
|
decreases activity |
ISO |
10 |
47,514,258 |
47,548,353 |
RGD:6480464 |
CTD |
| G |
Slc52a3 |
solute carrier family 52, riboflavin transporter, member 3 |
|
multiple interactions |
EXP |
3 |
142,360,661 |
142,365,285 |
RGD:6480464 |
CTD |
| G |
Slc9a2 |
solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2 |
|
multiple interactions |
EXP |
9 |
39,832,184 |
39,916,242 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
multiple interactions |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
multiple interactions |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
multiple interactions |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
multiple interactions |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
|
multiple interactions |
ISO |
5 |
3,531,163 |
3,584,401 |
RGD:6480464 |
CTD |
| G |
Trpc1 |
transient receptor potential cation channel, subfamily C, member 1 |
|
multiple interactions |
ISO |
8 |
100,770,833 |
100,821,420 |
RGD:6480464 |
CTD |
| G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
|
decreases activity |
ISO |
8 |
5,472,515 |
5,577,537 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Xbp1 |
X-box binding protein 1 |
|
multiple interactions |
ISO |
14 |
86,151,910 |
86,156,975 |
RGD:6480464 |
CTD |
Term paths to the root
|